309950-83-2Relevant academic research and scientific papers
Phenylsilane as an active amidation reagent for the preparation of carboxamides and peptides
Ruan, Zheming,Lawrence, R. Michael,Cooper, Christopher B.
, p. 7649 - 7651 (2006)
The use of phenylsilane as a mild coupling reagent for amidation reactions is reported. Applicability to both solution- and solid-phase chemistry has been demonstrated for a variety of amines and carboxylic acids.
Inhibition of the α-carbonic anhydrase from Vibrio cholerae with amides and sulfonamides incorporating imidazole moieties
De Vita, Daniela,Angeli, Andrea,Pandolfi, Fabiana,Bortolami, Martina,Costi, Roberta,Di Santo, Roberto,Suffredini, Elisabetta,Ceruso, Mariangela,Del Prete, Sonia,Capasso, Clemente,Scipione, Luigi,Supuran, Claudiu T.
, p. 798 - 804 (2017/06/09)
We discovered novel and selective sulfonamides/amides acting as inhibitors of the α-carbonic anhydrase (CA, EC 4.2.1.1) from the pathogenic bacterium Vibrio cholerae (VchCA). This Gram-negative bacterium is the causative agent of cholera and colonises the
2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents
-
, (2008/06/13)
Pyrimidine derivatives of the formula (I), wherein: Q1 and Q2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one or both Q1 and Q2 are substituted on a ring carbon by one substituent of the formula (Ia) or (Ia′), wherein: Y, Z, n, m, Q3, G, R1, are as defined within; and pharmaceutically acceptable salts and in in vivo hydrolyzable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
-
, (2008/06/13)
Compounds of formula (I) wherein: R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; p is 0-4; wherein the values of R1 may be the same or different; R2 is sulphamoyl or a group B—E—; wherein B is optionally substituted as defined within and is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C1-6alkyl, phenyl, a heterocyclic group, phenylC1-6alkyl or (heterocyclic group)C1-6alkyl; E is C(O)—, N(Ra)C(O)—, —C(O)N(Ra)—, —S(O)r—, —SO2N(Ra)— or —N(Ra)SO2—; wherein Ra is hydrogen or C1-6alkyl optionally substituted as defined within and r is 1-2; q is 0-2; wherein the values of R2 may be the same or different; and wherein p+q=1-5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof are described. Processes for their manufacture and their use as inhibitors of cell cycle kinases, particularly CDK2, CDK4 and/or CDK6 are also described.
